Market Research Logo

Peritoneal Cancer - Pipeline Review, H1 2018

Peritoneal Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H1 2018, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 12, 66, 44, 15, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 7 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Peritoneal Cancer - Overview
Peritoneal Cancer - Therapeutics Development
Peritoneal Cancer - Therapeutics Assessment
Peritoneal Cancer - Companies Involved in Therapeutics Development
Peritoneal Cancer - Drug Profiles
Peritoneal Cancer - Dormant Projects
Peritoneal Cancer - Discontinued Products
Peritoneal Cancer - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Peritoneal Cancer, H1 2018
Table 2: Number of Products under Development by Companies, H1 2018
Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 7: Number of Products under Development by Universities/Institutes, H1 2018
Table 8: Products under Development by Companies, H1 2018
Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Table 14: Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Table 15: Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Table 16: Products under Development by Universities/Institutes, H1 2018
Table 17: Number of Products by Stage and Target, H1 2018
Table 18: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Table 19: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Table 20: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Table 21: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Table 22: Number of Products by Stage and Mechanism of Action, H1 2018
Table 23: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Table 24: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Table 25: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Table 26: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Table 27: Number of Products by Stage and Route of Administration, H1 2018
Table 28: Number of Products by Stage and Molecule Type, H1 2018
Table 29: Peritoneal Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
Table 30: Peritoneal Cancer - Pipeline by AbbVie Inc, H1 2018
Table 31: Peritoneal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
Table 32: Peritoneal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
Table 33: Peritoneal Cancer - Pipeline by Altor BioScience Corp, H1 2018
Table 34: Peritoneal Cancer - Pipeline by Amgen Inc, H1 2018
Table 35: Peritoneal Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
Table 36: Peritoneal Cancer - Pipeline by Astellas Pharma Inc, H1 2018
Table 37: Peritoneal Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018
Table 38: Peritoneal Cancer - Pipeline by AstraZeneca Plc, H1 2018
Table 39: Peritoneal Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018
Table 40: Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
Table 41: Peritoneal Cancer - Pipeline by Bayer AG, H1 2018
Table 42: Peritoneal Cancer - Pipeline by BeiGene Ltd, H1 2018
Table 43: Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Table 44: Peritoneal Cancer - Pipeline by Boston Biomedical Inc, H1 2018
Table 45: Peritoneal Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018
Table 46: Peritoneal Cancer - Pipeline by Caladrius Biosciences Inc, H1 2018
Table 47: Peritoneal Cancer - Pipeline by Celgene Corp, H1 2018
Table 48: Peritoneal Cancer - Pipeline by Celldex Therapeutics Inc, H1 2018
Table 49: Peritoneal Cancer - Pipeline by Celsion Corp, H1 2018
Table 50: Peritoneal Cancer - Pipeline by CerRx Inc, H1 2018
Table 51: Peritoneal Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2018
Table 52: Peritoneal Cancer - Pipeline by Clovis Oncology Inc, H1 2018
Table 53: Peritoneal Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Table 54: Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018
Table 55: Peritoneal Cancer - Pipeline by Eisai Co Ltd, H1 2018
Table 56: Peritoneal Cancer - Pipeline by Eli Lilly and Co, H1 2018
Table 57: Peritoneal Cancer - Pipeline by EpiThany Inc, H1 2018
Table 58: Peritoneal Cancer - Pipeline by Epizyme Inc, H1 2018
Table 59: Peritoneal Cancer - Pipeline by Exelixis Inc, H1 2018
Table 60: Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Table 61: Peritoneal Cancer - Pipeline by Fate Therapeutics Inc, H1 2018
Table 62: Peritoneal Cancer - Pipeline by Gene Techno Science Co Ltd, H1 2018
Table 63: Peritoneal Cancer - Pipeline by Genelux Corp, H1 2018
Table 64: Peritoneal Cancer - Pipeline by Genentech Inc, H1 2018
Table 65: Peritoneal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018
Table 66: Peritoneal Cancer - Pipeline by Glycotope GmbH, H1 2018
Table 67: Peritoneal Cancer - Pipeline by Gradalis Inc, H1 2018
Table 68: Peritoneal Cancer - Pipeline by Hemispherx Biopharma Inc, H1 2018
Table 69: Peritoneal Cancer - Pipeline by Ignyta Inc, H1 2018
Table 70: Peritoneal Cancer - Pipeline by ImmunoGen Inc, H1 2018
Table 71: Peritoneal Cancer - Pipeline by Immunovaccine Inc, H1 2018
Table 72: Peritoneal Cancer - Pipeline by Innate Pharma SA, H1 2018
Table 73: Peritoneal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Table 74: Peritoneal Cancer - Pipeline by Johnson & Johnson, H1 2018
List of Figures
Figure 1: Number of Products under Development for Peritoneal Cancer, H1 2018
Figure 2: Number of Products under Development by Companies, H1 2018
Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
Figure 4: Number of Products by Top 10 Targets, H1 2018
Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report